Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESSO 43 | Exploring cryoablation and robotic-assisted lumpectomy in breast cancer treatment

Rosa Di Micco • 3 Oct 2024
ESSO 43
Breast Cancer
ICE3

Rosa Di Micco, MD, PhD, San Raffaele Scientific and Research Hospital in Milan, Italy, highlights trials exploring promising potential of innovative techniques in breast cancer treatment, specifically the ICE3 trial on cryoablation for early-stage breast cancer, and a randomized trial (NCT03440398) on robotic-assisted lumpectomy. She emphasizes the importance of exploring these advancements to assess their benefits for patients, noting the exciting nature of these novel approaches. This interview took place at the ESSO 43 Congress in Antwerp, Belgium.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Rosa Di Micco

The potential of AI in imaging for improved breast cancer detection and care
1:04
The potential of AI in imaging for improved breast cancer detection and care
Rosa Di Micco • 3 Oct 2024
CINDERELLA: AI app trial helps breast cancer pts visualize surgical outcomes for better satisfaction
1:05
CINDERELLA: AI app trial helps breast cancer pts visualize surgical outcomes for better satisfaction
Rosa Di Micco • 3 Oct 2024
AXSANA: reevaluating the necessity of axillary dissection in breast cancer treatment
0:39
AXSANA: reevaluating the necessity of axillary dissection in breast cancer treatment
Rosa Di Micco • 3 Oct 2024
Evolving role of axillary surgery in breast cancer after neoadjuvant chemotherapy
4:37
Evolving role of axillary surgery in breast cancer after neoadjuvant chemotherapy
Rosa Di Micco • 3 Oct 2024

Related Videos

CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals